[go: up one dir, main page]

AU2002232401A1 - Compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's disease - Google Patents

Compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's disease

Info

Publication number
AU2002232401A1
AU2002232401A1 AU2002232401A AU3240102A AU2002232401A1 AU 2002232401 A1 AU2002232401 A1 AU 2002232401A1 AU 2002232401 A AU2002232401 A AU 2002232401A AU 3240102 A AU3240102 A AU 3240102A AU 2002232401 A1 AU2002232401 A1 AU 2002232401A1
Authority
AU
Australia
Prior art keywords
alzheimer
stimulating
disease
compositions
microglial activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002232401A
Inventor
Michael Mullan
Jun Tan
Terrence Town
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Florida
Original Assignee
University of South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Florida filed Critical University of South Florida
Publication of AU2002232401A1 publication Critical patent/AU2002232401A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
AU2002232401A 2000-11-03 2001-11-05 Compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's disease Abandoned AU2002232401A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24560800P 2000-11-03 2000-11-03
US60/245,608 2000-11-03
PCT/US2001/042909 WO2002036166A2 (en) 2000-11-03 2001-11-05 Compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's disease

Publications (1)

Publication Number Publication Date
AU2002232401A1 true AU2002232401A1 (en) 2002-05-15

Family

ID=22927376

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002232401A Abandoned AU2002232401A1 (en) 2000-11-03 2001-11-05 Compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's disease

Country Status (6)

Country Link
US (1) US20020102259A1 (en)
EP (1) EP1349575A2 (en)
AU (1) AU2002232401A1 (en)
CA (1) CA2428023A1 (en)
MX (1) MXPA03003919A (en)
WO (1) WO2002036166A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003284968A1 (en) * 2002-10-25 2004-05-13 University Of South Florida Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
WO2010065776A2 (en) * 2008-12-03 2010-06-10 The Salk Institute For Biological Studies Identification of neuroprotective agents using pro-inflammatory human glial cells
EP2950102A1 (en) 2014-05-30 2015-12-02 Biocross, S.L. Method for the diagnosis of alzheimer s disease and mild cognitive impairment
EP3067699A1 (en) 2015-03-11 2016-09-14 Neuron Bio, S.A. Method for diagnosing alzheimer's disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001259215A1 (en) * 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same

Also Published As

Publication number Publication date
WO2002036166A2 (en) 2002-05-10
EP1349575A2 (en) 2003-10-08
WO2002036166A3 (en) 2003-01-30
MXPA03003919A (en) 2003-09-25
CA2428023A1 (en) 2002-05-10
US20020102259A1 (en) 2002-08-01
WO2002036166A8 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
AU2002219824A1 (en) Compositions and methods for diagnosing alzheimer's disease
AU2002328343A1 (en) Wax-based compositions and the use thereof as body care agents
AU2001233299A1 (en) Methods for treating alzheimer's disease
AU2001273132A1 (en) Compounds to treat alzheimer's disease
AU2001252135A1 (en) Therapeutic agents
AU2001278084A1 (en) Model for alzheimer's disease and other neurodegenerative diseases
HUP0302486A3 (en) Antimicrobial and deodorant compositions and process for preparing the same
AU3113500A (en) Compositions for treating alzheimer's disease and other amyloidoses
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
ZA200210278B (en) 3-azabicyclo(3.1.0)hexane derivatives useful in therapy.
AU2001290239A1 (en) Medicinal composition
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
AU5647601A (en) Hair treatment compositions
AU2001274877A1 (en) Pest treatment composition
AU2001273972A1 (en) Hair treatment composition
AU2001232866A1 (en) Skin care compositions
AU2001248760A1 (en) Preventives/remedies for alzheimer's disease
GB0009609D0 (en) Therapeutic compositions
AU2002232401A1 (en) Compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's disease
AU4426801A (en) Composition based on sphingolipid and beta-hydroxy-acid for skin care
AU2002215187A1 (en) S-adenosylmethionine and derivatives thereof for the treatment and prevention ofalzheimer's disease
AU2002222557A1 (en) Interferon therapeutic effect-potentiating agents
AU2002218494A1 (en) Medicinal compositions and process for producing the same
AU2001275696A1 (en) Therapeutic agent